Home
About
Who We Are
Our Team
Our Partners
Strategy
Broad Spectrum Approach
No Approved Therapies
"One Bug, One Drug" Problem
"One Drug, Many Bugs" Solution
Technology
Viral Envelope Targeting
Membrane-Active Agents
Pipeline
Intellectual Property Assets
Publications
Contact
Preparing For Tomorrow’s Viral Threats, Today.
Led by antiviral experts and seasoned executives, our team is devoted to translating antiviral research breakthroughs into urgently needed medicines.
Find out more
We Don’t Aim for One. We Aim for All.
We are driven by our “one drug, many bugs” vision that will lead to cures for a wide range of viral infections affecting billions of people worldwide.
Find out more
Exploiting the Achilles Heel of Viral Infection.
TSG has developed a unique set of antiviral peptides that target medically important viruses with high potency and selectivity.
Find out more
“The one-bug, one-drug approach is inadequate.”
Anthony Fauci
M.D., Director, National Institute of Allergy and Infectious Diseases
LEARN MORE
Our Team
Uniting the Best from Science and Business to bring together diverse expertise.
LEARN MORE
Our Pipeline
TSG’s drug candidates exhibit both direct-acting and broad-spectrum antiviral activity.
LEARN MORE
Our Solution
Our “One Drug, Many Bugs” approach will strengthen preparedness measures worldwide.
LEARN MORE
Technology
By translating antiviral research breakthroughs into urgently needed medicines, we aim to make a positive impact worldwide.
LEARN MORE